Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parexel International, a global biopharmaceutical services provider, has established a strategic functional service provider relationship with Eli Lilly and Company, to support study start-up and site monitoring of clinical trials throughout the Asia/Pacific region.
Subscribe to our email newsletter
Parexel will assist Lilly in bringing efficiencies to its clinical research studies to help meet Lilly’s development and commercialisation goals.
The collaboration will allow Lilly to focus on its relationships with investigators and regulators and increase its flexibility, productivity and efficiency.
Eli Lilly and Company Global Clinical Development VP Jeff Kasher said that the strategic agreement enables the firm to leverage Parexel’s expertise in clinical trial monitoring and site start-up services throughout the Asia/Pacific region, which will increase its ability to speed innovative medicines to patients.
Parexel International chairman and CEO Josef von Rickenbach said that the company has developed extensive local expert resources and capabilities for conducting high quality trials and is pleased to have been selected as a strategic partner by Lilly to help them accelerate development.
Boston, Massachusetts-based Parexel International offers knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries.